Remedy Place—the social wellness club with locations in West Hollywood, Soho, Flatiron, and Boston—has moved further into at-home protocols with the launch of its NAD+ Smart Pen, a self-administered injectable now available directly through its online platform. The device delivers between 50 and 125mg of pharmaceutical-grade NAD+ per dose via subcutaneous injection, produced in MHRA and GMP-certified facilities and third-party tested at 99.9% purity. It’s offered in three formats: a single pen at $499, a two-month supply at $849, and a three-month supply at $1,199, with subscription pricing reducing costs by 15% across all tiers.
The underlying proposition is straightforward. NAD+—a coenzyme present in every cell—is central to energy metabolism, DNA repair, and cellular signalling, with levels declining over time. The argument for injectable delivery over oral supplementation is bioavailability: rather than navigating inconsistent absorption through the digestive system, the compound is delivered directly into the bloodstream at a controlled dose. What’s shifting is access. Protocols that were previously limited to clinical or specialist settings are now being repositioned for at-home use, on-demand and without supervision. The research base remains in progress—far from universally settled—but interest from performance medicine and longevity-focused practitioners has been building steadily. The Smart Pen reflects that broader direction. Not a new idea, but a new format—bringing a clinic-adjacent intervention into the consumer environment, with all the convenience, and questions, that implies. Visit.
